Pulmonary Artery Denervation

This policy addresses pulmonary artery denervation (PADN) by any method and states PADN is considered experimental, investigational and not covered for all indications, including pulmonary arterial hypertension (PAH) and PAH subtypes (Groups 1–5) such as idiopathic PAH. Coverage is excluded for all PADN techniques (e.g., radiofrequency ablation, high‑frequency stimulation, remote magnetic navigation, therapeutic intravascular ultrasound/TIVUS) because current evidence is insufficient—limited by small, nonrandomized or short‑term studies—and larger multicenter randomized controlled trials are required before routine coverage.

"Pulmonary artery denervation (by any method) is considered experimental, investigational and/or unproven for all indications and therefore not covered, including treatment of pulmonary arterial hyp..."

Sign up to see full coverage criteria, indications, and limitations.